Significance of recently identified peptides in hypertension: Endothelin, natriuretic peptides, adrenomedullin, leptin

Medical Clinics of North America

Volumn 88, Issue 1, 2004, Pages 39-62

  Savoia, Carmine ^a   Schiffrin, Ernesto L ^a  

^a CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENOMEDULLIN; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; ENDOTHELIN; LEPTIN; NATRIURETIC FACTOR; NATRIURETIC PEPTIDE TYPE C; PEPTIDE; VASOCONSTRICTOR AGENT;

BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CORONARY ARTERY DISEASE; HEART FAILURE; HUMAN; HYPERTENSION; KIDNEY DISEASE; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PEPTIDE ANALYSIS; PRIORITY JOURNAL; PROTEIN FUNCTION; REGULATORY MECHANISM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; STATISTICAL SIGNIFICANCE;

EID: 0742287693     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0025-7125(03)00122-6     Document Type: Review

References (147)

1. Lüscher T.F., Vanhoutte P.M. The endothelium: modulator of cardiovascular function. 1990;CRC Press, Boca Raton, FL.
2. Furchgott R.F., Zawadzki J.V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 288:1980;373-376.
3. Hickey K.A., Rubanyi G., Paul R.J., Highsmith R.F. Characterization of a coronary vasoconstrictor produced by cultured endothelial cells. Am J Physiol. 248:1985;C550-C556.
4. Yanagisawa M., Kurihara H., Kimura S., Tomobe Y., Kombayashi M., Mitsui Y., et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 332:1988;411-415.
5. Lüscher T.F., Tanner F.C. Endothelial regulation of vascular tone and growth. Am J Hypertens. 6:1993;S283-S293.
6. Schiffrin E.L., Touyz M.R. Vascular biology of endothelin. J Cardiovasc Pharmacol. 32:(suppl 3):1998;S2-S13.
7. Intengan H.D., Schiffrin E.L. Structure and mechanical properties of resistance arteries in hypertension: role of adhesion molecules and extracellular matrix determinants. Hypertension. 36:2000;312-318.
8. Schiffrin E.L., Deng L.Y., Sventek P., Day R. Enhanced expression of endothelin-1 gene in resistance arteries in severe human essential hypertension. J Hypertens. 15:1997;57-63.
9. Han A.W.A., Resink T.J., Scott-Burden T., Powell J., Dohi Y., Buhler F.R. Stimulation of endothelial mRNA and secretion in rat vascular smooth muscle cells: a novel autocrine function. Cell Regul. 1:1990;649-659.
10. Moe G.W., Albernaz A., Naik G.O., Kirchengast M., Stewart D.J. Beneficial effects of long-term selective endothelin type A receptor blockade in canine experimental heart failure. Cardiovasc Res. 39:1998;571-579.
11. Inoue A., Yanagisawa M., Kimura S., Kasuya Y., Miyauchi T. The human endothelin family: 3 structurally and pharmacologically distinct isopeptides predicted by 3 separate genes. Proc Natl Acad Sci U S A. 86:1989;2863-2867.
12. Malek A., Izumo S. Physiological fluid shear stress causes downregulation of endothelin-1 mRNA in bovine aortic endothelium. Am J Physiol. 263:1992;C389-C396.
13. Boulanger C., Lüscher T.F. Release of endothelin from the porcine aorta. Inhibition by endothelium-derived nitric oxide. J Clin Invest. 85:1990;587-590.
14. Quehenberger P., Exner M., Sunder-Plassmann R., et al. Leptin induces endothelin-1 endothelial cells in vitro. Circ Res. 90:2002;711-718.
15. Delerive P., Martin-Nizard F., Chinetti G., Trottein F., Fruchart J.C., Najib J., et al. Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ Res. 85:1999;394-402.
16. Iglarz M., Touyz M.R., Amiri F., Lavoie M.F., Diep Q.N., Schiffrin E.L. Effect of peroxisome proliferator-activated receptor-alpha and -gamma activators on vascular remodellingin endothelial-dependent hypertension. Atheroscler Thromb Vasc Biol. 23:2003;45-51.
17. Ergul S., Parish D.C., Puett D., Ergul A. Racial differences in plasma endothelin-1 concentrations in individuals with essential hypertension. Hypertension. 28:1996;652-655.
18. De Nucci G., Thomas R., D'Orléans-Juste P., Antunes E., Walder C., Warner T.D., et al. Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc Natl Acad Sci U S A. 85:1988;9797-9800.
19. Kurihara Y., Kurihara H., Suzuki H., Kodama T., Naemura K., Nagai R., et al. Elevated blood pressure and craniofacial abnormalities in mice deficient in endothelin-1. Nature. 368:1994;703-710.
20. Clouthier D.E., Hosoda K., Richardson J.A., Williams S.C., Yanagisawa H., Kuwaki T., et al. Cranial and cardiac neural crest defects in endothelin-A receptor-deficient mice. Development. 125:1998;813-824.
21. Hosoda K., Hammer R.E., Richardson J.A., Baynash A.G., Cheung J.C., Giaid A., et al. Targeted and natural (piebald-lethal) mutations of endothelin-B receptor gene produce megacolon associated with spotted coat colour in mice. Cell. 79:1994;1267-1276.
22. Cardillo C., Campia U., Kilcoyne C.M., Bryant M.B., Panza J.A. Improved endothelium-dependent vasodilation after blockade of endothelin receptors in patients with essential hypertension. Circulation. 105:2002;452-456.
23. Cardillo C., Kilcoyne C.M., Waclawiw M., Cannon R.O. III, Panza J.A. Role of endothelin in the increased vascular tone of patients with essential hypertension. Hypertension. 33:1999;753-758.
24. Verhaar M.C., Strachan F.E., Newby D.E., Cruden N.L., Koomans H.A., Rabelink T.J., et al. Endothelin-A receptor antagonist-mediated vasodilation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation. 97:1998;752-756.
25. Iglarz M., Benessiano J., Philip I., Vuillaumier-Barrot S., Lasocki S., Hvass U., et al. Preproendothelin-1 gene polymorphism is related to a change in vascular reactivity in the human mammary artery in vitro. Hypertension. 39:2002;202-213.
26. Park J.B., Touyz R.M., Chen X., Schiffrin E.L. Chronic treatment with a superoxide dismutase mimetic prevents vascular remodeling and progression of hypertension in salt-loaded stroke-prone spontaneously hypertensive rats. Am J Hypertens. 15:2002;78-84.
27. Intengan H.D., Schiffrin E.L. Structure and mechanical properties of resistance arteries in hypertension: role of adhesion molecules and extracellular matrix determinants. Hypertension. 36:2000;312-318.
28. Schiffrin E.L. Role of endothelin-1 in hypertension and vascular disease. Am J Hypertens. 14:2001;83S-89S.
29. Matsuura A., Yamochi W., Hirata K., Kawashima S., Yokoyama M. Stimulatory interaction between vascular endothelial growth factor and endothelin-1 on each gene expression. Hypertension. 32:1998;89-95.
30. Krum H., Viskoper R.J., Lacourcière Y., Budde M., Charlon V. The effect of an endothelin receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension investigators. N Engl J Med. 338:1998;784-790.
31. Nakov R., Pfarr E., Eberle S. Darusentan: an effective endothelin A receptor antagonist for treatment of hypertension. Am J Hypertens. 15:2002;583-589.
32. Park J.B., Schiffrin E.L. Cardiac and vascular fibrosis and hypertrophy in aldosterone-infused rats: role of endothelin-1. Am J Hypertens. 15:2002;164-169.
33. Ammarguellat F., Larouche I.I., Schiffrin E.L. Myocardial fibrosis in DOCA-salt hypertensive rats: effects of endothelin ET(A) receptor antagonism. Circulation. 103:2001;319-324.
34. Ammarguellat F.Z., Gannon P.O., Amiri F., Schiffrin E.L. Fibrosis, matrix metalloproteinases, and inflammation in the heart of DOCA-salt hypertensive rats: role of ET(A) receptors. Hypertension. 39:2002;679-684.
35. Pacher R., Stanek B., Hulsmann M., Koller-Strametz J., Berger R., Schuller M., et al. Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. J Am Coll Cardiol. 27:1996;633-641.
36. Kiowski W., Sutsch G., Hunziker P., Muller P., Kim J., Oechslin E., et al. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet. 346:1995;732-736.
37. Amala L., Cleland J.G.F., Crabble S., Ford S., Trackray S., Houghton T., et al. Clinical trials update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and REINASSANCE and cachexia and cholesterol in heart failure. Highlights of the Scientific Sessions of the American College of Cardiology, 2001. Eur J Heart Fail. 3:2001;381-387.
38. Kalra P., Moon J., Coats A. Do results of the ENABLE (Endothelin Antagonist Bosentan for lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure? Int J Cardiol. 85:2002;195.
39. Plato C.F., Pollock D.M., Garvin J.L. Endothelin inhibits thick ascending limb chloride flux via ET(B) receptor-mediated NO release. Am J Physiol. 279:2000;F326-F333.
40. Tostes R.C., Touyz R.M., He G., Ammarguellat F., Schiffrin E.L. Endothelin A receptor blockade decreases expression of growth factors and collagen and improves matrix metalloproteinase-2 activity I in kidneys from stroke prone spontaneously hypertensive rats. J Cardiovasc Pharmacol. 39:2002;892-900.
41. Brooks D.P., dePalma P.D., Gellai M., Nambi P., Ohlstein E.H., Elliot J.D., et al. Nonpeptide endothelin receptor antagonists. III. Effect of SB 209670 and BQ123 on acute renal failure in anesthetized dogs. J Pharmacol Exp Ther. 271:1994;769-775.
42. Benigni A., Colosio V., Brena C., Bruzzi I., Bertani T., Remuzzi G. Unselective inhibition of endothelin receptors reduces renal dysfunction in experimental diabetes. Diabetes. 47:1998;450-456.
43. Cardillo C., Campia U., Bryant M.B., Panza J.A. Increased activity of endogenous endothelin in patients with type II diabetes mellitus. Circulation. 106:2002;1783-1787.
44. Lerman A., Edwards B.S., Hallet J.W., Heulbein D.M., Sandberg S.M., Burnett J.C. Jr. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med. 325:1991;997-1001.
45. Lerman A., Holmes D.R., Bell M.R., Garrat K.N., Nishimura R.A., Burnett J.C. Jr. Endothelin in coronary endothelial dysfunction and early atherosclerosis in humans. Circulation. 92:1995;2426-2431.
46. Tomoda H. Plasma endothelin-1 in acute myocardial infarction with heart failure. Am Heart J. 125:1993;667-672.
47. Schiffrin E.L., Intengan H.D., Thibault G., Touyz R.M. Clinical significance of endothelin in cardiovascular disease. Curr Opin Cardiol. 12:1997;354-367.
48. Giaid A., Polak J.M., Gaitonde V., Hamid Q.A., Mascocco G., Legon S., et al. Distribution of endothelin-like immunoreactivity and mRNA in the developing and adult human lung. Am J Respir Cell Mol Biol. 4:1991;50-58.
49. Stewart D.J., Levy R.D., Cernacek P., Langleben D. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann Intern Med. 114:1991;464-469.
50. Giaid A., Yanagisawa M., Langleben D., Michel R.P., Levy R., Shennib H., et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med. 328:1993;1732-1739.
51. Ooi H., Colucci W.S., Givertz M.M. Endothelin mediates increased pulmonary vascular tone in patients with heart failure: demonstration by direct intrapulmonary infusion of sitaxsentan. Circulation. 106:2002;1618-1621.
52. Cody R.J., Haas G.J., Binkley P.F., Capers Q., Kelley R. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation. 85:1992;504-509.
53. Dupuis J., Cernacek P., Tardif J.C., Tardif J.C., Stewart D.J., Gosselin G., et al. Reduced pulmonary clearance of endothelin-1 in pulmonary hypertension. Am Heart J. 135:1998;614-620.
54. Rubin L.J., Badesch D.B., Barst R.J., Galie N., Black C.M., Keogh A., et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 346:2002;896-903.
55. Gardner D.G., Deschepper C.F., Ganong D.F., Hane S., Fiddes J., Baxter J.D., et al. Extra-atrial expression of the gene for atrial natriuretic factor. Proc Natl Acad Sci U S A. 83:1986;6697-6701.
56. Gunning M., Brenner B.M. Urodilatin: a potent natriuretic peptide of renal origin. Curr Opin Nephrol Hypertens. 2:1993;857-862.
57. Chien K.R., Knowlton K.U., Zhu H., Chien S. Regulation of cardiac gene expression during myocardial growth and hypertrophy: molecular studies of adaptive physiological response. FASEB J. 5:1991;3037-3046.
58. Sagnella G.A. Measurement and significance of circulating natriuretic peptides in cardiovascular disease. Clin Sci. 95:1998;519-529.
59. Freitag M.H., Larson M.G., Levy D., Benjamin E.J., Wang T.J., Leip E.P., et al. Plasma brain natriuretic peptide levels and blood pressure tracking in the Framingham heart study. Hypertension. 41:2003;978-983.
60. Darbar D., Davidson N.C., Gillespie N., Choy A.M., Lang C.C., Shyr Y., et al. Diagnostic value of B-type natriuretic peptide concentrations in patients with acute myocardial infarction. Am J Cardiol. 78:1996;284-287.
61. Wei C.M., Aarhus L.L., Miller V.M., Burnett C.J. Jr. The action of C-type natriuretic peptide in isolated canine arteries and veins. Am J Physiol. 264:1993;H71-H73.
62. Furuya M., Yoshida M., Minamino N., Kangawa K., Matsuo H. C-type natriuretic peptide is a growth inhibitor of rat VSMCs. Biochem Biophys Res Commun. 177:1991;927-931.
63. Kalra P.R., Anker S.D., Struthers A.D., Coats A.J. The role of C-type natriuretic peptide in cardiovascular medicine. Eur Heart J. 22:2001;997-1007.
64. Koller K.J., Goeddel D.V. Molecular biology of the natriuretic peptides and their receptors. Circulation. 86:1992;1081-1088.
65. Anand-Srivastava M.B., Sairam M.R., Cantin M. Ring-deleted analogs of atrial natriuretic factor inhibit adenylate cyclase/cAMP system: possible coupling of clearance atrial natriuretic factor receptors to adenylate cyclase/cAMP signal transduction system. J Biol Chem. 265:1990;8566-8572.
66. Charles C.J., Espiner E.A., Nicholls M.G., Richards A.M., Yandle T.G., Protter A., et al. Clearance receptors and endopeptidase 24.11: equal role in natriuretic peptide metabolism in conscious sheep. Am J Physiol. 271:1996;R373-R380.
67. Marin-Grez M., Fleming J.T., Steihausen M. Atrial natriuretic peptide causes pre-glomerular vasodilation and post-glomerular vasoconstriction in rat kidney. Nature. 324:1986;473-476.
68. Sonnenberg H., Honrath U., Chong C.K., Wilson D.R. Atrial natriuretic factor inhibits sodium transport in medullary collecting duct. Am J Physiol. 231:1986;1572-1573.
69. Chartier L., Schiffrin E.L., Thibault G., Garcia R. Atrial natriuretic factor inhibits the stimulation of aldosterone secretion by angiotensin, I.I., ACTH and potassium in vitro and angiotensin II-induced steroidogenesis in vivo. Endocrinology. 115:1984;2026-2028.
70. Dillingham M.A., Anderson R.J. Inhibition of vasopressin action by atrial natriuretic factor. Science. 250:1986;F963-F966.
71. Volpe M., Mele A.F., Indolfi C., De Luca N., Lembo G., Focaccio A., et al. Hemodynamic and hormonal effects of atrial natriuretic factor in patients with essential hypertension. J Am Coll Cardiol. 10:1987;787-793.
72. Volpe M., Cuocolo A., Vecchione F., Lembo G., Pignalosa S., Condorelli M., et al. Influence of volume expansion on hemodynamic effects of atrial natriuretic factor in rabbits. Am J Physiol. 256:1989;H852-H858.
73. Volpe M., De Luca N., Cappelli-Bigazzi M., Vecchine F., Lembo G., Condorelli M., et al. Atrial natriuretic factor potentiates forearm reflex vasoconstriction induced by cardiopulmonary receptor deactivation in man. Circulation. 77:1988;849-855.
74. Schultz H.D., Gardner D.G., Deschepper C.F., Coleridge H.M., Coleridge J.C., Vagal C. Fibre blockade abolishes sympathetic inhibition by atrial natriuretic factor. Am J Physiol. 155:1988;R6-R13.
75. Itoh H., Pratt R.E., Dzau V.J. Atrial natriuretic polypeptide inhibits hypertrophy of vascular smooth muscle cells. J Clin Invest. 86:1990;1690-1697.
76. Vesely D.L. Atrial natriuretic peptides in pathophysiological diseases. Cardiovasc Res. 51:2001;647-658.
77. Steinhelper M.E., Cochrane K.L., Field L.J. Hypotension in transgenic mice expressing atrial natriuretic factor fusion genes. Hypertension. 16:1990;301-307.
78. Ogawa Y., Itoh H., Tamura N., Suga S., Yoshimasa T., Uehira M., et al. Molecular cloning of the complementary DNA and gene that encode mouse brain natriuretic peptide and generation of transgenic mice that overexpress the brain natriuretic peptide gene. J Clin Invest. 93:1994;1911-1921.
79. Jhon S.W.M., Krege J.H., Oliver P.M., Hagaman J.R., Hodgin J.B., Pang S., et al. Genetic decreases in atrial natriuretic peptide and salt sensitive hypertension. Science. 267:1995;679-681.
80. Lopez M.J., Wong S.K.-F., Kishimoto I., Dubois S., Mach V., Friesen J., et al. Salt-resistant hypertension in mice lacking the guanyl cyclase-A receptor for atrial natriuretic peptide. Nature. 378:1995;65-68.
81. Yokota N., Bruneau B.G., Kuroski T., de Bold M.L., de Bold A.J. Atrial natriuretic factor significantly contributes to the mineralocorticoid escape phenomenon: evidence for a guanylate cyclase-mediated pathway. J Clin Invest. 94:1994;1938-1946.
82. Rubattu S., Volpe M. The atrial natriuretic peptide: a changing view. J Hypertens. 19:2001;1923-1931.
83. Estrada D., Tellez M.J., Moya J., Fernandez-Durango R., Egido J., Fernandez-Cruz A. High plasma levels of endothelin-1 and atrial natriuretic peptide in patients with acute ischemic stroke. Am J Hypertens. 7:1994;1085-1089.
84. Rubattu S., Ridker P.M., Stampfer J.M., Volpe M., Hennekens C.H., Lindpaintner K. The gene encoding atrial natriuretic peptide and the risk of human stroke. Circulation. 100:1999;1722-1726.
85. Rubattu S., Volpe M., Kreutz R., Ganten U., Ganten D., Lindpaintner K. Chromosomal mapping of quantitative trait loci contributing to stroke in an animal model of complex human disease. Nat Genet. 13:1996;429-434.
86. Rubattu S., Lee M.A., De Paolis P., Giliberti R., Lombardi A., Gigante B., et al. Altered structure regulation an function of the gene encoding atrial natriuretic peptide in the stroke-prone spontaneously hypertensive rat. Circ Res. 85:1999;900-905.
87. Rubattu S., Giliberti R., Ganten U., Volpe M. A differential brain atrial natriuretic peptide expression co-segregates with occurrence of early stroke in the stroke prone phenotype of spontaneously hypertensive rat. J Hypertens. 17:1999;1849-1852.
88. Sagnella G.A. Atrial natriuretic peptide mimetics and vasopeptidase inhibitors. Cardiovasc Res. 51:2001;416-428.
89. Mitchell G.F., Izzo J.L., Lacourcière Y., et al. Omapatrilat reduces pulse pressure and proximal aortic stiffness in patients with systolic hypertension. Results of the Conduit Hemodynamics of Omapatrilat International Research study. Circulation. 105:2002;2955-2961.
90. Corti R., Burnett J.C., Rouleau J.L., Ruschitzka F., Lüscher T.F. Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease? Circulation. 104:2001;1856-1862.
91. Campbell D.J. Vasopeptidase inhibition. A double-edged sword? Hypertension. 41:2003;383-389.
92. Kitamura K., Kangawa M., Ichiki Y., Nakamura S., Matsuo H., Eto T. Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun. 192:1993;553-560.
93. Martinez A., Cutitta F. Adrenomedullin. 1998;IOS Press, Washington.
94. Sugo S., Minamino N., Shoji H., Kangawa K., Matsuo H. Effects of vasoactive substances and cAMP related compounds on adrenomedullin production in cultured vascular smooth muscle cells. FEBS Lett. 369:1995;311-314.
95. Chun T.H., Itoh H., Ogawa Y., Tamura N., Takaya K., Igaki T., et al. Shear stress augments expression of C-type natriuretic peptide and adrenomedullin. Hypertension. 29:1997;1296-1302.
96. Shimosawa T., Ito Y., Ando K., Kitamura K., Kangawa K., Fujita T. Proadrenomedullin NH2-terminal 20 peptide, a new product of the adrenomedullin gene, inhibits norepinephrine overflow from nerve ending. J Clin Invest. 96:1995;1672-1676.
97. Shimekake Y., Nagata K., Ohta S., Kambayashi Y., Teraoka H., Kitamura K., et al. Adrenomedullin stimulates two signal transduction pathways, cAMP accumulation and Ca mobilization, in bovine aortic endothelial cells. J Biol Chem. 270:1995;4412-4417.
98. Kato H., Shichiri M., Marumo F., Hirata Y. Adrenomedullin as an autocrine/paracrine apoptosis survival factor for rat endothelial cells. Endocrinology. 138:1997;2615-2620.
99. Caron K.M., Smithies O. Extreme hydrops fetalis and cardiovascular abnormalities in mice lacking a functional adrenomedullin gene. Proc Natl Acad Sci U S A. 98:2001;615-619.
100. Kohno M., Kano H., Horio T., Yokokawa K., Yasunari K., Takeda T. Inhibition of endothelin production by adrenomedullin in vascular smooth muscle cells. Hypertension. 25:1995;1185-1190.
101. Tsuruda T., Kato J., Kitamura K., Kawamoto M., Kuwasako K., Inamura T., et al. An autocrine or a paracrine role of adrenomedullin in modulating cardiac fibroblast growth. Cardiovasc Res. 43:1999;958-967.
102. Horio T., Kohno M., Kano H., Ikeda M., Yasumari K., Yokokawa K., et al. Adrenomedullin as a novel antimigration factor of vascular smooth muscle cells. Circ Res. 77:1995;660-664.
103. Shimosawa T., Shibagaki Y., Ishibashi K., Kitamura K., Kangawa K., Kato S., et al. Adrenomedullin, an endogenous peptide, counteracts cardiovascular damage. Circulation. 105:2002;106-111.
104. Shimosawa T., Ogihara T., Matsui H., Asano T., Ando K., Fujita T. Deficiency of adrenomedullin induces insulin resistance by increasing oxidative stress. Hypertension. 41:2003;1080-1085.
105. Shimuzo K., Tanaka H., Sunamori M., Maruno F., Shichiri M. Adrenomedullin receptor antagonism by calcitonin gene-related peptide (8-37) inhibits carotid artery neointimal hyperplasia after balloon injury. Circ Res. 85:1999;1199-1205.
106. Imai Y., Shindo T., Maemura K., Sata M., Saito Y., Kurihara Y., et al. Resistance to neointimal hyperplasia and fatty streak formation in mice with adrenomedullin overexpression. Arterioscler Thromb Vasc Biol. 22:2002;1310-1315.
107. Yamasaki M., Kawai J., Nakaoka T., Ogita T., Tojo A., Fujita T. Adrenomedullin overexpression to inhibit cuff-induced arterial intimal formation. Hypertension. 41:2003;302-307.
108. Parkes DG. Cardiovascular actions of adrenomedullin in conscious sheep. Am J Physiol 268:H2574-8.
109. Szokodi I., Kinnunen P., Tavi P., Weckstrom M., Toth M., Ruskoaho H. Evidence for cAMP-independent mechanism mediating the effects of adrenomedullin, a new inotropic peptide. Circulation. 97:1998;1062-1070.
110. Cockcroft J.R., Noon J.P., Gardner-Medwin J., Bennet T. Haemodynamic effects of adrenomedullin in human resistance and capacitance vessels. Br J Clin Pharmacol. 44:1997;57-60.
111. Samson W.K. Adrenomedullin and the control of fluid and electrolyte homeostasis. Ann Rev Physiol. 61:1999;363-389.
112. Nishikimi T., Yoshihara F., Kanazawa A., Okano I., Horio T., Nagaya N., et al. Increased circulating and renal adrenomedullin in rats with malignant hypertension. Am J Physiol Regul Integr Comp Physiol. 281:2001;R2779-R2787.
113. Nishimatsu H., Hirata Y., Shindo T., Kurihara H., Kakoki M., Nagata D., et al. Role of endogenous adrenomedullin in the regulation of vascular tone and ischemic renal injury: studies on transgenic/knockout mice of adrenomedullin gene. Circ Res. 90:2002;657-663.
114. Dobrzynski E., Wang C., Chao L. Adrenomedullin gene delivery attenuates hypertension, cardiac remodeling, and renal injury in deoxycorticosterone acetate-salt hypertensive rats. Hypertension. 36:2000;995-1001.
115. Tanaka M., Kitamura K., Ishizaka Y., Ishiyama Y., Kato J., Kangawa K., et al. Plasma adrenomedullin in various diseases and exercise-induced change inn adrenomedullin in healthy subjects. Int Med. 34:1995;728-733.
116. Jougasaki M., Burnett J.C. Jr. Adrenomedullin: potential in physiology and pathophysiology. Life Sci. 66:2000;855-872.
117. Kato J., Kitamura K., Matsui E., Tanaka M., Ishizaka Y., Kita T., et al. Plasma adrenomedullin and natriuretic peptides in patients with essential or malignant hypertension. Hypertens Res. 22:1999;61-65.
118. Kato J., Kitamura K., Kuwasako K., et al. Plasma adrenomedullin in patients with primary aldosteronism. Am J Hypertens. 8:1995;997-1000.
119. Nishikimi T., Tadokoro K., Mori Y., Wang X., Akimoto K., Yoshihara F., et al. Ventricular adrenomedullin system in the transition from LVH to heart failure in rats. Hypertension. 41:2003;512-518.
120. Kato J., Kobayashi K., Etoh T., Tanaka M., Kitamura K., Imamura T., et al. Plasma adrenomedullin concentration in patients with heart failure. J Clin Endocrinol Metab. 81:1996;180-193.
121. Jougasaki M., Grantham J.A., Redfield R.R., Burnett J.C. Jr. Regulation of cardiac adrenomedullin in heart failure. Peptides. 22:2001;1841-1850.
122. Chao J., Kato K., Zhang J.J., Dobrzynski E., Wang C., Agata J., et al. Human adrenomedullin gene delivery protects against cardiovascular remodelling and renal injury. Peptides. 22:2001;1731-1737.
123. Nagaya N., Satoh T., Nishikimi T., Uematsu M., Furuichi S., Sakamaki F., et al. Hemodynamic, renal, and hormonal effects of adrenomedullin infusion in patients with congestive heart failure. Circulation. 101:2000;498-503.
124. Eto T, Washimine H, Kato J, Kitamura K, Yamamoto Y. Adrenomedullin and proadrenomedullin N-terminal 20 peptide in impaired renal function. Kidney Int 49:S148-9.
125. Sato K., Hirata Y., Imai T., Iwashina M., Marumo F. Characterization of immunoreactive adrenomedullin in human plasma and urine. Life Sci. 57:1995;189-194.
126. Shinomiya K., Ohmori K., Ohyama H., Hosomi N., Takahashi T., Osaka K., et al. Association of plasma adrenomedullin with carotid atherosclerosis in chronic ischemic stroke. Peptides. 22:2001;1873-1880.
127. Rademaker M.T., Charles C.J., Cooper G.J., Coy D.H., Espiner E.A., Lewis L.K., et al. Combined endopeptidase inhibition and adrenomedullin in sheep with experimental heart failure. Hypertension. 39:2002;93-98.
128. Oehler M.K., Norbury C., Hague S., Rees M.C., Bicknell R. Adrenomedullin inhibits hypoxic cell death by upregulation of Bcl-2 in endothelial cancer cells: a possible promotion mechanism for tumour growth. Oncogene. 20:2001;2937-2945.
129. Maffei M., Halaas J., Ravussin E., Pratley R.E., Lee G.H., Zhang Y., et al. Leptin levels in human and rodent: measurement of plasma leptin and Ob RNA in obese and weight-reduced subject. Nat Med. 1:1995;1155-1161.
130. Considine R.V., Sinha M.K., Heiman M.L., Kriauciuanas A., Stephens T.W., Nyce M.R., et al. Serum immunoreactive leptin concentrations in normal-weight and obese humans. N Engl J Med. 334:1996;292-295.
131. Rahmouni K., Haynes W.G., Morgan D.A., Mark A.L. Selective resistance to central neural administration of leptin in agouti obese mice. Hypertension. 39:2002;486-490.
132. Finck B.N., Johnson R.W. Tumour necrosis factor-α regulates secretion of the adipocyte-derived cytokine, leptin. Microsc Res Tech. 50:2000;209-215.
133. Haynes W.G., Sivitz W.I., Morgan D.A., Walsh S.A., Mark A.L. Sympathetic and cardiorenal actions of leptin. Hypertension. 30:(part 2):1997;619-623.
134. Eikelis N., Schlaich M., Aggarwal A., Kaye D., Esler M. Interactions between leptin and the human sympathetic nervous system. Hypertension. 41:2003;1072-1079.
135. Sierra-Honigmann M.R., Nath A.K., Murakami C., Garcia-Cardena G., Papapetropoulos A., Sessa W.C., et al. Biological action of leptin as an angiogenic factor. Science. 281:1998;1683-1686.
136. Bouloumie A., Marumo T., Lafontan M., Busse R. Leptin induces oxidative stress in human endothelial cells. FASEB J. 13:1999;1231-1238.
137. Parhami F., Tintut Y., Ballard A., Fogelman A.M., Demer L.L. Leptin enhances the calcification of vascular cells: artery wall as a target of leptin. Circ Res. 88:2001;954-960.
138. Singhal A., Farooqi I.S., Cole T.J., O'Rahilly S., Fewtrell M., Kattenhorn M., et al. Influence of leptin on arterial distensibility: a novel link between obesity and cardiovascular disease? Circulation. 106:2002;1919-1924.
139. Konstantinides S., Schafer K., Cschnick S., Loskutoff D. Jr. Leptin-dependent platelet aggregation and arterial thrombotic disease in obesity. J Clin Invest. 108:2001;1533-1540.
140. Wallace A.M., McMahon A.D., Packard C.J., Kelly A., Shepherd J., Gaw A., et al. Plasma leptin and the risk of cardiovascular disease in the west of Scotland Coronary Prevention Study (WOSCOPS). Circulation. 104:2001;3052-3056.
141. Ballerman B.J. A role for leptin in glomerulosclerosis? Kidney Int. 56:1999;1154-1155.
142. Wolf G., Chen S., Han D.C., Ziyadeh F.N. Leptin and renal disease. Am J Kidney Dis. 39:2002;1-11.
143. Hall J.E., Hildebrandt D.A., Kuo J. Obesity hypertension: role of leptin and sympathetic nervous system. Am J Hypertens. 14:2001;103S-115S.
144. Agata J., Masuda A., Takada M., Higashiura K., Muratami H., Miyazaki Y., et al. High plasma immunoreactive leptin level in essential hypertension. Am J Hypertens. 10:1997;1171-1174.
145. Frubeck G. Pivotal role of nitric oxide in the control of blood pressure after leptin administration. Diabetes. 48:1999;903-908.
146. Considine R.D. Regulation of leptin production. Rev Endocr Metab Disord. 2:2001;357-363.
147. Goetze S., Bungenstock A., Czupalla C., Eilers F., Stawowy P., Kintscher U., et al. Leptin induces endothelial cell migration though Akt, which is inhibited by PPARγ-ligands. Hypertension. 40:2002;748-754.